The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up

Responses can be achieved with dasatinib or nilotinib after failure of 2 prior tyrosine kinase inhibitors (TKIs). We report on 48 chronic myeloid leukemia patients sequentially treated with 3 TKIs: 34 with dasatinib after imatinib/nilotinib failure and 14 with nilotinib after imatinib/dasatinib fail...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Garg, Ravin J., Kantarjian, Hagop, O'Brien, Susan, Quintás-Cardama, Alfonso, Faderl, Stefan, Estrov, Zeev, Cortes, Jorge
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2009
Témata:
Clinical Trials and Observations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3952810/
https://ncbi.nlm.nih.gov/pubmed/19729517
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-05-221531
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky